0.08%
4.13%
-16.07%
-26.35%
2.34%
0.23%
163.25%
AI Spotlight on ROVI
Company Description
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally.The company distributes other products that are licensed from other laboratories.Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers.
The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material.It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets.The company serves wholesalers, doctors, nursing staff, pharmacists, and patients.
It has a collaboration with Moderna, Inc.for manufacturing mRNA COVID-19 vaccine candidate.The company was incorporated in 1946 and is headquartered in Madrid, Spain.
Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
Market Data
| Last Price | 65.55 |
| Change Percentage | 0.08% |
| Open | 66 |
| Previous Close | 65.5 |
| Market Cap ( Millions) | 3323 |
| Volume | 98834 |
| Year High | 94.8 |
| Year Low | 57.2 |
| M A 50 | 62.47 |
| M A 200 | 75.82 |
Financial Ratios
| FCF Yield | 1.92% |
| Dividend Yield | 0.00% |
| ROE | 31.67% |
| Debt / Equity | 0.00% |
| Net Debt / EBIDTA | -7.30% |
| Price To Book | 6.38 |
| Price Earnings Ratio | 21.21 |
| Price To FCF | 51.95 |
| Price To sales | 4.16 |
| EV / EBITDA | 13.74 |
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Marketing
Expected Growth : 10 %
What the company do ?
Marketing from Laboratorios Farmaceuticos Rovi, S.A. refers to the promotional strategies and tactics used to reach healthcare professionals and patients, increasing brand awareness and driving sales of their pharmaceutical products.
Why we expect these perspectives ?
Laboratorios Farmaceuticos Rovi's 10% marketing growth is driven by increasing demand for specialty pharmaceuticals, successful product launches, and strategic partnerships. Additionally, the company's focus on digital marketing and e-commerce platforms has expanded its customer reach, while investments in sales force effectiveness and customer relationship management have improved sales productivity.
Segment n°2 -> Manufacturing
Expected Growth : 12 %
What the company do ?
Manufacturing from Laboratorios Farmaceuticos Rovi, S.A. refers to the production of pharmaceutical products, including sterile injectables, at their facilities in Spain.
Why we expect these perspectives ?
Laboratorios Farmaceuticos Rovi, S.A.'s 12% growth in manufacturing is driven by increasing demand for generic medicines, strategic partnerships, and expansion into emerging markets. Additionally, investments in R&D, process optimization, and cost savings initiatives have improved operational efficiency, contributing to the company's growth momentum.
Laboratorios Farmaceuticos Rovi, S.A. Products
| Product Range | What is it ? |
|---|---|
| Enbrel | Etanercept injection is a tumor necrosis factor (TNF) inhibitor used to treat autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriasis. |
| Humira | Adalimumab injection is a TNF inhibitor used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. |
| Remicade | Infliximab injection is a TNF inhibitor used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. |
| Simponi | Golimumab injection is a TNF inhibitor used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. |
| Cimzia | Certolizumab pegol injection is a TNF inhibitor used to treat autoimmune diseases such as rheumatoid arthritis and Crohn's disease. |
| Biosimilar products | Rovi's biosimilar products are used to treat various autoimmune diseases, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. |
Laboratorios Farmaceuticos Rovi, S.A.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Laboratorios Farmaceuticos Rovi, S.A. is medium due to the presence of alternative pharmaceutical products in the market.
Bargaining Power Of Customers
The bargaining power of customers for Laboratorios Farmaceuticos Rovi, S.A. is low due to the company's strong brand reputation and customer loyalty.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Laboratorios Farmaceuticos Rovi, S.A. is medium due to the presence of multiple suppliers in the market.
Threat Of New Entrants
The threat of new entrants for Laboratorios Farmaceuticos Rovi, S.A. is high due to the growing demand for pharmaceutical products and the ease of entry into the market.
Intensity Of Rivalry
The intensity of rivalry for Laboratorios Farmaceuticos Rovi, S.A. is high due to the presence of several established players in the pharmaceutical industry.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 10.82% |
| Debt Cost | 3.95% |
| Equity Weight | 89.18% |
| Equity Cost | 6.34% |
| WACC | 6.08% |
| Leverage | 12.13% |
Laboratorios Farmaceuticos Rovi, S.A. : Quality Control
Laboratorios Farmaceuticos Rovi, S.A. passed 8 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CAMX.ST | Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine … |
| ZEAL.CO | Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, … |
| ALK-B.CO | ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis … |
| ALKS | Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its … |
| GMAB.CO | Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Rovi
A-Score
1-Year Total Return ->
🥈
ALK-Abelló
A-Score
1-Year Total Return ->
🥉
Genmab
A-Score
1-Year Total Return ->
4
Camurus
A-Score
1-Year Total Return ->
5
Alkermes
A-Score
1-Year Total Return ->
6
